Featured Research

from universities, journals, and other organizations

Therapeutic Delivery Of A Gene To Dysfunctional Nerves

Date:
June 26, 2009
Source:
Journal of Clinical Investigation
Summary:
In many sensory neuronopathies, painful conditions affecting sensory nerves outside the brain and spinal cord, the affected nerves are in a region known as the DRG. These conditions are difficult to treat. However, researchers have now developed an approach to target therapeutic genes to DRG nerves, and used it to reduce sensory nerve dysfunction in a mouse model of Sandhoff disease, an inherited condition in which many nerves, including those in the DRG, are affected.

In many sensory neuronopathies, painful conditions affecting sensory nerves outside the brain and spinal cord, the affected nerves are in a region known as the DRG. These conditions are difficult to treat. However, researchers have now developed an approach to target therapeutic genes to DRG nerves, and used it to reduce sensory nerve dysfunction in a mouse model of Sandhoff disease, an inherited condition in which many nerves, including those in the DRG, are affected.

Medical conditions that affect sensory nerves outside the brain and spinal cord are known as sensory neuronopathies. These conditions, which are extremely painful, include shingles and can be caused by anticancer drugs such as cisplatin. In many sensory neuronopathies, the nerves that are dysfunctional are those in a region of the body known as the dorsal root ganglion (DRG), and these conditions are particularly difficult to treat. However, Lawrence Chan and colleagues, at Baylor College of Medicine, Houston, have developed an approach to target therapeutic genes to nerves in the DRG, and used it to reduce sensory nerve dysfunction in a mouse model of Sandhoff disease, an inherited condition in which many nerves, including those in the DRG, are affected.

The authors developed a system to generate helper-dependent adenoviruses that targeted only DRG nerves. These were used to deliver genes to DRG nerves in mice and found to be dramatically more efficient at gene delivery than nontargeted helper-dependent adenoviruses. In mice lacking the Hexb gene, which are consider a mouse model of Sandhoff disease, administration of DRG-targeted helper-dependent adenoviruses carrying the Hexb gene restored Hexb expression in DRG nerves and eliminated sensory nerve dysfunction. The authors hope this approach could be developed for treating different forms of DRG sensory neuronopathies.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Terashima et al. DRG-targeted helper-dependent adenoviruses mediate selective gene delivery for therapeutic rescue of sensory neuronopathies in mice. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI39038

Cite This Page:

Journal of Clinical Investigation. "Therapeutic Delivery Of A Gene To Dysfunctional Nerves." ScienceDaily. ScienceDaily, 26 June 2009. <www.sciencedaily.com/releases/2009/06/090615171509.htm>.
Journal of Clinical Investigation. (2009, June 26). Therapeutic Delivery Of A Gene To Dysfunctional Nerves. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/06/090615171509.htm
Journal of Clinical Investigation. "Therapeutic Delivery Of A Gene To Dysfunctional Nerves." ScienceDaily. www.sciencedaily.com/releases/2009/06/090615171509.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins